• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Study Finds Drug Combinations for Pseudomonas and Staphylococcus Co-infections

by
November 11, 2026
in Biology
Reading Time: 6 mins read
0
Study Finds Drug Combinations for Pseudomonas and Staphylococcus Co-infections

Study Finds Drug Combinations for Pseudomonas and Staphylococcus Co-infections

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers published a study in Discover Bacteria on June 11, 2025, evaluating specific antimicrobial drug combinations against co-infections of Pseudomonas aeruginosa and Staphylococcus aureus. The investigation focused on how these two prevalent bacterial pathogens interact when present together in both planktonic and biofilm phases. The study aimed to identify therapeutic strategies that could prevent the spread of antimicrobial resistance by leveraging combination therapy rather than relying on single-agent treatments. The findings suggest that certain drug pairs demonstrate synergistic effects, potentially offering a viable alternative for managing complex polymicrobial infections that typically fail to respond to standard antibiotic regimens.

The research team, led by Amit Sharma and colleagues, utilized a diverse set of clinical isolates to model these co-infections. They analyzed 52 clinical isolates of P. aeruginosa and 43 isolates of S. aureus to identify strains with specific resistance and virulence profiles. Through phenotypic, genotypic, and antimicrobial susceptibility testing, the researchers selected specific sensitive and resistant strains for co-culture preparation. The resistant strains identified were PA-14 for P. aeruginosa and PS-107 for S. aureus, while the sensitive strains were PA-27 and PS-100. This selection process ensured that the study could compare the effects of drug combinations on both susceptible and multidrug-resistant bacterial communities.

The experimental design involved creating 1:1 co-cultures of the selected strains to mimic the competitive and cooperative interactions observed in natural infections. The researchers assessed the antimicrobial susceptibility of these co-cultures in both planktonic and biofilm forms. They employed the checkerboard method to evaluate the synergistic, additive, or antagonistic effects of various drug combinations. The study measured the Minimum Inhibitory Concentration (MIC) for planktonic cultures and the Minimum Biofilm Inhibitory Concentration (MBIC) for biofilm cultures. By comparing these metrics against pure cultures of the individual bacteria, the team could quantify how the presence of the second pathogen altered the susceptibility of the first.

Initial susceptibility testing revealed significant differences between the pure cultures and the co-cultures. In the planktonic phase, the co-cultures exhibited MIC shifts that generally mirrored the pure cultures of P. aeruginosa, suggesting a competitive dynamic where P. aeruginosa maintained its dominant profile. However, in the biofilm phase, the co-cultures demonstrated enhanced antibiotic resistance. The MBICs for the majority of drugs exceeded the ranges observed in pure cultures, indicating a cooperative behavioral change.

The drug combination studies focused on a shortlisted set of agents, including colistin, linezolid, trimethoprim, nitrofurantoin, and vancomycin. These drugs were selected based on their individual susceptibility profiles against the selected strains. The researchers tested 12 different drug combinations against the planktonic co-cultures. For the resistant strain co-culture PA-14/PS-107, 33.3% of the combinations showed synergistic interactions. In the sensitive strain co-culture PA-27/PS-100, 41.7% of the combinations demonstrated synergy. Colistin was a key component in many of these synergistic pairs, showing significant effects when combined with linezolid, trimethoprim, nitrofurantoin, and vancomycin. The fractional inhibitory concentration index (FICI) values for these combinations were well below the threshold for synergy, confirming their potential efficacy.

The evaluation of biofilm co-cultures revealed a more limited but distinct set of effective combinations. Among 24 drug combinations tested against the resistant biofilm co-culture, only 8.3% showed synergistic effects. Specifically, the combinations of colistin with linezolid and colistin with vancomycin prevented biofilm formation in the resistant strains. In contrast, the sensitive strain biofilm co-culture responded more favorably, with 80% of the tested combinations showing synergy. Colistin combined with linezolid, vancomycin, trimethoprim, and nitrofurantoin all demonstrated significant antibiofilm activity.

The study noted that while the synergistic combinations were effective, the individual drugs involved often displayed inhibitory effects against the pure cultures within their susceptible ranges. This observation mitigates the perceived benefit of synergy in some contexts, as the drugs are already effective against the individual pathogens. However, the study emphasized a notable decrease in the MICs of the combined drugs when compared to their use against pure bacterial cultures. In many cases, the MIC reduction was at least 50%. This reduction suggests that adjusted doses of the combined drugs could be more effective than monotherapy, allowing for lower individual drug concentrations while maintaining therapeutic efficacy. This approach could help minimize the side effects associated with high-dose antibiotic administration.

The molecular characterization of the isolates provided insights into the mechanisms driving resistance and virulence. The resistant P. aeruginosa strain PA-14 harbored the blaNDM-1 gene, which confers resistance to carbapenems and other beta-lactam antibiotics. Virulence factors such as pyoverdine and pyocyanin in P. aeruginosa, and staphyloxanthin and slime in S. aureus, were also confirmed. The presence of biofilm-associated genes like pslA, pvdA, icaA, and icaD further supported the selection of these strains for the co-culture studies. These molecular markers correlated with the phenotypic observations of strong biofilm formation and pigment production.

The discussion section of the study explored the ecological dynamics between the two pathogens. It suggested that the transition from a solitary to a co-existing lifestyle impacts the susceptibility and pathogenic profiles of both bacteria. The competitive nature of P. aeruginosa in the planktonic phase contrasts with the cooperative interactions observed in the biofilm phase. The study referenced previous research indicating that exogenous alginate from P. aeruginosa can shield S. aureus biofilms from antibiotic effects. Additionally, the production of pyoverdine by P. aeruginosa facilitates iron acquisition, potentially outcompeting S. aureus for this essential nutrient. These interactions create a complex environment where the virulence and resistance of both pathogens are modulated, making treatment more challenging.

Limitations of the study include the in vitro nature of the experiments, which may not fully replicate the complex conditions of human infections. The study focused on a specific set of drug combinations and strains, and the results may not generalize to all clinical scenarios. The researchers acknowledged that further investigation into the molecular mechanisms of synergy and resistance development is needed. Additionally, the potential for drug-induced nephrotoxicity was noted for the synergistic combinations, particularly those involving colistin. Despite these limitations, the study provides valuable insights into the management of P. aeruginosa and S. aureus co-infections. It highlights the potential of repurposing existing drugs in combination to combat multidrug-resistant polymicrobial infections, offering a strategic alternative to the development of novel antibiotics.

The initial characterization across the broader collection of clinical isolates established widespread antimicrobial resistance alongside high biofilm capacity. Broth micro-dilution assays against seventeen antimicrobial agents demonstrated that 55.8 percent of the fifty-two Pseudomonas aeruginosa isolates were multidrug resistant, although all remained completely inhibited by colistin. Among the carbapenem-resistant Pseudomonas aeruginosa isolates, molecular testing detected the blaNDM-1 gene in 10.3 percent of strains, whereas blaVEB-1, blaGES-1, and blaOXA-48 were entirely absent. For the forty-three Staphylococcus aureus isolates screened across thirteen agents, 76.7 percent were multidrug resistant, even though all isolates maintained susceptibility to linezolid, nitrofurantoin, vancomycin, and rifampin. The mecA resistance gene appeared in 2.3 percent of the staphylococcal isolates, while 11.6 percent carried the beta-lactamase gene blaZ. Biofilm assessments classified 65.4 percent of Pseudomonas aeruginosa isolates and 32.6 percent of Staphylococcus aureus isolates as strong producers, highlighting the strong tendency of both clinical cohorts toward matrix-enclosed growth.

Phenotypic assays and gene detection also detailed an extensive array of virulence factors among the clinical isolates. Pyoverdine emerged as the predominant pigment in Pseudomonas aeruginosa, produced by 67.3 percent of isolates, while pyocyanin and pyorubin appeared in 30.7 percent and 1.92 percent, respectively. Enzymatic profiling revealed that 82.7 percent of the Pseudomonas aeruginosa isolates produced gelatinase, 67.3 percent generated lipase, and 1.92 percent produced urease. In Staphylococcus aureus, staphyloxanthin pigment was detected in 67.4 percent of isolates, and 32.6 percent formed slime, with gelatinase, lipase, and urease present across 76.7 percent of strains. Gene profiling identified the pslA biofilm gene in 6.5 percent of biofilm-forming Pseudomonas aeruginosa and the pvdA siderophore gene in 8.6 percent of pyoverdine producers. Within the staphylococcal group, the intercellular adhesion genes icaA and icaD appeared in 12.5 percent and 4.2 percent of biofilm producers, respectively, while the staphylococcal enterotoxin gene seA occurred in 7.0 percent of isolates.

The researchers proposed that the membrane-permeabilizing activity of colistin underpins the observed synergy within these dual-species architectures. At lower concentrations, colistin disrupts the Gram-negative outer membrane and damages the staphylococcal cell surface, accelerating divalent ion leakage and permitting co-administered agents to penetrate bacterial barriers that typically exclude them. This mechanism helped overcome substantial tolerance surges recorded in biofilm co-cultures, where the resistant combination PA-14 and PS-107 exhibited minimum biofilm inhibitory concentration increments exceeding sixteenfold for tetracycline and vancomycin, eightfold for linezolid, and fourfold for nitrofurantoin compared to solitary staphylococcal biofilms. Furthermore, the authors observed practical clinical alignment among these synergistic compounds, noting that colistin, linezolid, vancomycin, trimethoprim, and nitrofurantoin share overlapping administration routes across inhalation, oral, ophthalmic, and intravenous formulations.

Subject of Research: Antimicrobial combination therapy for Pseudomonas aeruginosa and Staphylococcus aureus co-infections

Article Title: The antimicrobial spectrum to manage the co-infections of Pseudomonas aeruginosa and Staphylococcus aureus

Article References: Sharma, A., Tripathi, S., Rani, K., Vibhuti, A., Pandey, R. P., & Raj, V. S. (2025). The antimicrobial spectrum to manage the co-infections of Pseudomonas aeruginosa and Staphylococcus aureus. Discover Bacteria, 2(1), Article 18. https://doi.org/10.1007/s44351-025-00028-4

Image Credits: AI Generated

DOI: 10.1007/s44351-025-00028-4

Keywords: Pseudomonas aeruginosa, Staphylococcus aureus, Antimicrobial resistance, Biofilm, Drug combination, Colistin, Linezolid, Vancomycin, Polymicrobial infection, In vitro study, antimicrobial, spectrum

News Source: Kristina Jarvis. (November 11, 2026). Study Finds Drug Combinations for Pseudomonas and Staphylococcus Co-infections. Scienmag.

Tags: antimicrobialAntimicrobial Resistancebiofilmcolistindrug combinationin vitro studylinezolidpolymicrobial infectionPseudomonas aeruginosaspectrumStaphylococcus aureusvancomycin
Share12Tweet7Share2ShareShareShare1

Related Posts

High-Intensity Interval Exercise Delays Body Cooling During Temperate Water Immersion

High-Intensity Interval Exercise Delays Body Cooling During Temperate Water Immersion

November 19, 2026
Camera Trap Distance Sampling Reveals High Red Brocket Deer Density in Bolivia

Camera Trap Distance Sampling Reveals High Red Brocket Deer Density in Bolivia

November 19, 2026

Pollack Tracking Reveals Distinct Behavioral Contingents That Challenge Stock Assumptions

November 19, 2026

Skin Morphology and Gene Networks Drive Heat Tolerance in Lufeng Cattle

November 19, 2026

POPULAR NEWS

  • Anlotinib Combined with Cranial Radiotherapy Shows Promise for Lung Cancer Brain Metastases

    Anlotinib Combined with Cranial Radiotherapy Shows Promise for Lung Cancer Brain Metastases

    29 shares
    Share 12 Tweet 7
  • Curcumin Reduces Liver Steatosis in Rats by Altering Gut Microbiota and Epigenetics

    29 shares
    Share 12 Tweet 7
  • Air Sampling in Bat Caves Captures Mammalian Viruses Across Optimized Volumes

    29 shares
    Share 12 Tweet 7
  • Rimegepant Provides Meaningful Relief as Second- or Third-Line Acute Migraine Therapy

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Review Examines Central Nervous System Risks From Low-Frequency Sound and Infrasound

Surgery Fails to Outperform Conservative Care for Pain in Fibrous Dysplasia

Food Package Label Awareness Shows No Link to Body Weight Blame

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.